Oncolytics Biotech (ONCY) said Wednesday that translational data for its intravenously delivered immunotherapeutic agent, pelareorep, showed effectiveness of the therapy across multiple tumor types.
The data confirmed viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment, the company said.
Oncolytics Biotech added that the data reinforces pelareorep's ability to convert immunologically "cold" tumors into "hot" phenotypes, paving the way for registration-enabling trials.
Shares were up 2.7% in recent early trading.
Price: 1.16, Change: +0.03, Percent Change: +2.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.